0001415889-19-001366.txt : 20191122
0001415889-19-001366.hdr.sgml : 20191122
20191122073037
ACCESSION NUMBER: 0001415889-19-001366
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191120
FILED AS OF DATE: 20191122
DATE AS OF CHANGE: 20191122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CASEY MICHAEL D
CENTRAL INDEX KEY: 0001190435
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34912
FILM NUMBER: 191238697
MAIL ADDRESS:
STREET 1: ALLOS THERAPEUTICS, INC.
STREET 2: 11080 CIRCLEPOINT ROAD, SUITE 200
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222711928
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
4
1
form4-11222019_071124.xml
X0306
4
2019-11-20
1
0000816284
CELGENE CORP /DE/
CELG
0001190435
CASEY MICHAEL D
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT
NJ
07901
true
false
false
false
Common Stock
2019-11-20
4
D
0
143638
0
D
0
I
By Family Trust
Stock Option (right to buy)
27.69
2019-11-20
4
D
0
24666
0
D
2020-06-16
Common Stock
24666
0
D
Stock Option (right to buy)
29
2019-11-20
4
D
0
18600
0
D
2021-06-15
Common Stock
18600
0
D
Stock Option (right to buy)
31.80
2019-11-20
4
D
0
18600
0
D
2022-06-13
Common Stock
18600
0
D
Stock Option (right to buy)
59.06
2019-11-20
4
D
0
18600
0
D
2023-06-12
Common Stock
18600
0
D
Stock Option (right to buy)
88.50
2019-11-20
4
D
0
20700
0
D
2024-07-01
Common Stock
20700
0
D
Stock Option (right to buy)
112.16
2019-11-20
4
D
0
10000
0
D
2025-06-17
Common Stock
10000
0
D
Stock Option (right to buy)
99.98
2019-11-20
4
D
0
11000
0
D
2026-06-15
Common Stock
11000
0
D
Stock Option (right to buy)
121.04
2019-11-20
4
D
0
10500
0
D
2027-06-14
Common Stock
10500
0
D
Stock Option (right to buy)
77.38
2019-11-20
4
D
0
13266
0
D
2028-06-13
Common Stock
13266
0
D
Restricted Stock Unit
0
2019-11-20
4
D
0
300
0
D
Common Stock
300
0
D
Restricted Stock Unit
0
2019-11-20
4
D
0
970
0
D
Common Stock
970
0
D
Restricted Stock Unit
0
2019-11-20
4
D
0
4756
0
D
Common Stock
4756
0
D
Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
This option was fully exercisable.
Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
/s/ Jonathan Biller, Attorney-in-Fact
2019-11-22